---
document_datetime: 2025-04-04 09:36:41
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rxulti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: rxulti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.3169687
conversion_datetime: 2025-12-24 06:36:27.511685
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## RXULTI

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| II/0015              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 30/01/2025                          | 07/03/2025                                  | SmPC and PL                      |                                   |
| PSUSA/10698 /202407  | Periodic Safety Update EU Single assessment - brexpiprazole                                                                    | 13/02/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| R/0014              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 30/03/2023   | 26/05/2023   | SmPC, Annex II and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of RXULTI in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. RXULTI (brexpiprazole) is removed from the additional monitoring list as a new active substance following five years of authorisation. Therefore, the statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information, preceded by an inverted equilateral black triangle, is removed from the summary of product characteristics and the package leaflet. A few minor changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other relevant guideline(s).   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10698 /202107 | Periodic Safety Update EU Single assessment - brexpiprazole                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 10/02/2022   | n/a          |                         | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0013/G           | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished | 17/11/2021   | 31/10/2022   | SmPC, Labelling and PL  | To introduce additional pack sizes (EU/1/18/1294/008-011) in the Product Information and in 'EPAR - all Authorised presentations'. To update the wording related to lactose in section 2 of the Summary of Product Characteristics (SmPC) and to update local representatives in the Package Leaflet. To update Section 6.5 of the Danish SmPC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                      |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10698 /202101 | Periodic Safety Update EU Single assessment - brexpiprazole                                                                                                                                                                                                                                                                                                                                                                                 | 02/09/2021 | n/a | PRAC Recommendation - maintenance |
| PSUSA/10698 /202007 | Periodic Safety Update EU Single assessment - brexpiprazole                                                                                                                                                                                                                                                                                                                                                                                 | 11/02/2021 | n/a | PRAC Recommendation - maintenance |
| IA/0010             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                | 20/11/2020 | n/a |                                   |
| PSUSA/10698 /202001 | Periodic Safety Update EU Single assessment - brexpiprazole                                                                                                                                                                                                                                                                                                                                                                                 | 03/09/2020 | n/a | PRAC Recommendation - maintenance |
| IB/0008/G           | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 19/08/2020 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | control/testing takes place B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0007             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/07/2020 | 05/11/2020 | SmPC and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10698 /201907 | Periodic Safety Update EU Single assessment - brexpiprazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/01/2020 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0003             | Based on the Company Core Data Sheet of brexpiprazole, update of section 4.4 of the SmPC to add information regarding Impulse-control disorders and section 4.8 to add the adverse reactions 'Gambling disorder', 'Impulsive behaviour', 'Binge eating', 'Compulsive shopping' and 'Compulsive sexual behaviour' with a frequency 'unknown'. The Package Leaflet (PL) is updated accordingly. In addition, the MAH took the opportunity to clarify the wording regarding the posology in 'Patients taking strong CYP3A4 inducers' in SmPC section 4.2 as requested by EMA, and to perform additional editorials and minor changes throughout the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 14/11/2019 | 05/11/2020 | SmPC, Annex II and PL | Considering all available data, the CHMP agrees that the cases reported are suggestive of the possibility to develop impulse control disorders (ICDs) especially if brexpiprazole is co-administered with other medications, used off label, or in patients with co-morbidities. Brexpiprazole mechanism of action and its similarities with aripiprazole, despite not being alone sufficient to establish a causal relationship between ICDs and brexpiprazole use, are also suggestive of the possibility to develop gambling and other impulse control disorders. Accordingly, section 4.4 of the SmPC is updated to add information regarding Impulse- control disorders and section 4.8 to add the adverse reactions 'Gambling disorder', 'Impulsive behaviour', 'Binge eating', 'Compulsive shopping' and 'Compulsive sexual behaviour' with a frequency 'unknown'. The Package Leaflet (PL) is updated accordingly. |

<div style=\"page-break-after: always\"></div>

| IB/0005             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | 31/10/2019   | n/a        |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| PSUSA/10698 /201901 | Periodic Safety Update EU Single assessment - brexpiprazole                                      | 05/09/2019   | n/a        |                        | PRAC Recommendation - maintenance |
| T/0001              | Transfer of Marketing Authorisation                                                              | 02/10/2018   | 12/12/2018 | SmPC, Labelling and PL |                                   |